Noxsano

Executive Summary

Noxsano is a privately held medical technology company headquartered in Dayton, Ohio, founded in 2015. The company specializes in innovative wound care products that utilize a unique point-of-use nitric oxide generation technology via water-activated pads and gels. This approach has been clinically proven to significantly accelerate healing times for both human and veterinary applications. Noxsano's platform addresses a critical unmet need in the $20B+ global wound care market, particularly for chronic wounds such as diabetic ulcers and surgical sites, where infection and delayed healing are major challenges. The company's proprietary NO-generating mechanism offers a compelling alternative to traditional antimicrobial and healing agents, with potential for broad adoption across hospitals, clinics, and home care settings. While Noxsano operates in a competitive landscape, its differentiated technology and established clinical evidence position it for growth pending successful commercialization and strategic partnerships.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance for next-generation nitric oxide wound dressing70% success
• TBDPublication of additional clinical trial results demonstrating superiority over standard of care65% success
• TBDStrategic partnership or distribution agreement with a major wound care company50% success